According to the Silicon Valley Business Journal, CardioDX has postponed its IPO. The publication reported that the company cited unfavorable market conditions as the reason for the deferral. CardioDX was scheduled to start trading its stock on the NASDAQ under the ticker symbol “CDX” on November 14, 2013. Headquartered in Palo Alto, Calif., CardioDx is a molecular diagnostics company specializing in cardiovascular genomics. Investors include V-Sciences Investments, Longitude Venture Partners, Artiman Ventures, Kleiner Perkins Caufield & Byers, JP Morgan and Mohr Davidow Ventures.